A review of interaction studies between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues

  • J. S. Dixon
  • M. C. Page
Chapter
Part of the Inflammation and Drug Therapy Series book series (IDTH, volume 5)

Abstract

The potential for non-steroidal anti-inflammatory drug (NSAID) induced peptic ulceration in susceptible individuals [1], and the risk of complications in patients with existing ulcers [2], has led to the practice of co-prescribing these agents with H2-receptor antagonists or prostaglandin analogues. The major consumers of NSAIDs are patients with arthritis who are frequently elderly and are often already receiving multiple drug therapy. Such therapy provides considerable potential for drug interactions. Furthermore, the elderly frequently have decreased renal and hepatic function together with impaired absorption from the gut [3]. Therefore any observed interaction between NSAIDs and H2-receptor antagonists or prostaglandin analogues in the absence of other therapy, in young healthy subjects may be enhanced in patients, particularly in the elderly.

Keywords

Young Healthy Subject Prostaglandin Analogue High Performance Liquid Chromato Multiple Drug Therapy Pharmacokinetic Interaction Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Duggan J.M., Dobson J.A., Johnson H., Fahey P. Peptic ulcer and non-steroidal anti-inflammatory agents. Gut. 1986;27:929–933.PubMedCrossRefGoogle Scholar
  2. 2.
    CSM update. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions. 2. Br Med J. 1986;292:1190–1191.CrossRefGoogle Scholar
  3. 3.
    Dawling S., Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet. 1989;17:236–263.PubMedCrossRefGoogle Scholar
  4. 4.
    Ochs H.R., Greenblatt D.J., Matlis R., Weinbrenner J. Interaction of ibuprofen with the H2-receptor antagonists ranitidine and cimetidine. Clin Pharmacol Ther. 1985;38:648–651.PubMedCrossRefGoogle Scholar
  5. 5.
    Stephenson D.W., Small R.E., Wood J.H. et al. Effect of ranitidine and cimetidine on ibuprofen pharmacokinetics. Clin Pharm. 1988;7:317–321.PubMedGoogle Scholar
  6. 6.
    Forsyth D.R., Jayasinghe K.S.A., Roberts C.J.C. Do nizatidine and cimetidine interact with ibuprofen? Eur J Clin Pharmacol. 1988;35:85–88.PubMedCrossRefGoogle Scholar
  7. 7.
    Conrad K.A., Mayersohn M., Bliss M. Cimetidine does not alter ibuprofen kinetics after a single dose. Br J Clin Pharmacol. Br J Qin Pharmacol. 1984;18:624–626.CrossRefGoogle Scholar
  8. 8.
    Berardi R.R., Dressman J.B., Elta G.H., Szpunar G.J. Elevation of gastric pH with ranitidine does not affect the release characteristics of sustained release ibuprofen tablets. Biopharm Drug Dis. 1988;9:337–347.CrossRefGoogle Scholar
  9. 9.
    Delhotal-Landes B., Flouvat B., Liote F. et al. Phannacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers. Clin Pharmacol Ther. 1988;44:442–452.PubMedCrossRefGoogle Scholar
  10. 10.
    Dammann H.G., Simon-Schultz J., Bauermeister W. et al. Prevention of NSAID-induced gastric ulcer with prostaglandin analogues. Lancet. 1989;1:52–53.Google Scholar
  11. 11.
    Rietbrock N., Karim A., Nicholson P.A. Prevention of NSAID-induced gastric ulcer with prostaglandin analogues. Lancet. 1989;1:844–845.PubMedCrossRefGoogle Scholar
  12. 12.
    Muller P., Dammann H.G., Langer M., Leucht U., Simon B. Ranitidine improves the gastroduodenal tolerability of acemetacin and indomethacin without affecting the pharmacokinetics of both antirheumatics. Z Gastroenterol. 1989;27:83–86.PubMedGoogle Scholar
  13. 13.
    Howes C.A., Pullar T., Sourindhrin I. et al. Reduced steady-state plasma concentrations of chlorpromazine and indomethacin in patients receiving cimetidine. Eur J Clin Pharmacol. 1983;24:99–102.PubMedCrossRefGoogle Scholar
  14. 14.
    Corrocher R., Bambara L.M., Caramaschi P. et al. Effect of ranitidine on the absorption of aspirin. Digestion. 1987;37:178–183.PubMedCrossRefGoogle Scholar
  15. 15.
    Trnavska Z., Trnavsky K., Smondrk J. The effect of cimetidine on the pharmacokinetics of salicylic acid. Drugs Exp Clin Res. 1985;11:703–707.PubMedGoogle Scholar
  16. 16.
    Paton T.W., Walker S.E., Leung F.Y.K., Little A.H. Effect of cimetidine on bioavailability of enteric-coated aspirin tablets. Clin Pharm. 1983;2:165–166.PubMedGoogle Scholar
  17. 17.
    O’Laughlin J.C., Silvoso G.R., Ivey K.J. Effects of an H2—blocker on gastric ulcers in patients taking aspirin: a double-blind study. Gastroenterology. 1980;78(No.5 Part 2):1230.Google Scholar
  18. 18.
    Sullivan K.M., Small R.E. Rock WL et al. Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Clin Pharm. 1986;5:586–589.PubMedGoogle Scholar
  19. 19.
    Kreeft J., Bellamy N., Freeman D. Does chronic H2-antagonist administration alter steady-state flurbiprofen pharmacokinetics? Acta Pharmacol Toxicol. 1986;59(Suppl. V):Abstract 253:96.Google Scholar
  20. 20.
    Mailhot C., Dahl S.L., Ward J.R. The effect of cimetidine on serum concentrations of piroxicam. Pharmacotherapy. 1986;6:112–117.PubMedGoogle Scholar
  21. 21.
    Said S.A., Foda A.M. Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. Arzneim-Forsch Drug Res. 1989;39:790–792.Google Scholar
  22. 22.
    Dixon J.S., Lacey L.F., Pickup M.E., Langley S.J., Page M.C. A lack of pharmacokinetic interaction between ranitidine and piroxicam. Br J Clin Pharmacol. 1991;39:583–586.Google Scholar
  23. 23.
    Verbeeck R.K., Corman C.L., Wallace S.M. Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. Eur J Clin Pharmacol. 1988;35:521–527.PubMedCrossRefGoogle Scholar
  24. 24.
    Famham D.J. Studies of isoxicam in combination with aspirin, warfarin sodium and cimetidine. Semin Arthritis Rheum. 1982;12(Suppl. 2):179–183.CrossRefGoogle Scholar
  25. 25.
    Holford N.H.G., Altman D., Riegelman S. et al. Pharmacokinetic and pharmacodynamic study of cimetidine administered with naproxen. Clin Pharmacol Ther. 1981;29:251–252.Google Scholar
  26. 26.
    Scavone J.M., Greenblatt D.J., Matlis R., Harmatz J.S. Interaction of oxaprozin with acetaminophen, cimetidine and ranitidine. Eur J Clin Pharmacol. 1986;31:371–374.Google Scholar
  27. 27.
    Karim A., Smith M., Belliel S., Hunt T. Lack of drug-drug interaction between prostaglandin E, analogue misoprostol and NSAIDs. In: Proc Third Interscience World Conf Monte Carlo; 1989 (Abst).Google Scholar
  28. 28.
    Karim A., Rozek L.F., Leese P.T. Absorption of misoprostol (cytotec), an antiulcer prostaglandin, or aspirin is not affected when given concomitantly to healthy human subjects. Gastroenterology. 1989;92:1742.Google Scholar
  29. 29.
    Nicholson P.A., Karim A., Smith M. Pharmacokinetics of misoprostol in the elderly, in patients with renal failure and when co-administered with NSAID or antipyrine, propranolol or diazepam. J Rheumatol. 1990;17(Suppl. 20):33–37.Google Scholar
  30. 30.
    Hsyu P.H., Cox J.W., Pullen R.H., Gee W.L., Euter A.R. Pharmacokinetic interactions between arbaprostil and aspirin in humans. Biopharm Drug Disp. 1989;10:411–422.CrossRefGoogle Scholar
  31. 31.
    Unsworth J., Sturman S., Lunec J., Blake D.R. Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 1987;46:233–236.PubMedCrossRefGoogle Scholar
  32. 32.
    Dixon J.S., Bojar R., Bird H.A. Renal impairment in relation to non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 1988;47:260–264.PubMedCrossRefGoogle Scholar
  33. 33.
    Van Den Ouweland F.A., Gribnau F.W.J., Van Ginneken C.A.M., Tan Y., Van De Putte L.B.A. Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. Clin Pharmacol Ther. 1988;43:79–85.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • J. S. Dixon
    • 1
  • M. C. Page
    • 1
  1. 1.Division of GastroenterologyGlaxo Group Research LimitedGreenford, MiddlesexUK

Personalised recommendations